A343090 Stock Overview
Develops biological drugs with MoA to infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
HLB SCIENCE Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,989.00 |
| 52 Week High | ₩6,600.00 |
| 52 Week Low | ₩1,524.00 |
| Beta | 0 |
| 11 Month Change | 2.37% |
| 3 Month Change | -8.76% |
| 1 Year Change | 20.99% |
| 33 Year Change | -73.48% |
| 5 Year Change | n/a |
| Change since IPO | -54.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| A343090 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.0% | -8.1% | 2.9% |
| 1Y | 21.0% | 18.1% | -2.8% |
Return vs Industry: A343090 exceeded the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A343090 exceeded the KR Market which returned -2.8% over the past year.
Price Volatility
| A343090 volatility | |
|---|---|
| A343090 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A343090 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A343090's weekly volatility has decreased from 10% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Yoon Jongsun | www.hlbscience.com |
HLB SCIENCE Inc. develops biological drugs with MoA to infectious diseases. Its pipeline includes DD-S052P, a candidate that exterminates germs and eliminates endotoxins; DD-A279, a new treatment to cure Alzheimer's Diseases by controlling LPS and Gram-negative bacteria; and DD-A514, a diagnosis kit for Alzheimer's diseases. The company was formerly known as Dandi Bio Science Co.,Ltd.
HLB SCIENCE Inc. Fundamentals Summary
| A343090 fundamental statistics | |
|---|---|
| Market cap | ₩32.58b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A343090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A343090 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A343090 perform over the long term?
See historical performance and comparison